CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.
CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.
CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
1620 Beacon Place
Oxnard, CA 93033
We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.
Our Investor Presentation
CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020
CBD, Cannabis and the Cannabiz
In the news
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)
CURE's Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD)CCHMC to Seek Formulary...
LOS ANGELES, April 14, 2022 -- Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond stores. Sera Labs...
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico
COFEPRIS (Mexico's equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE's Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE's patented Oral Thin Film (OTF) dose form CUREform™OXNARD,...
Sera Labs, a Subsidiary of CURE Pharmaceutical, Consummates Exclusive International Distribution Agreement With Leading Canadian Distributor
Northern Response International To Distribute Seratopical Revolution® Masstige LineLOS ANGELES and TORONTO, Dec. 09, 2021 -- The Sera Labs, a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR) today announced its global expansion into Canada by...
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue...
CURE Pharmaceutical Reports Second Quarter 2021 Revenue Rose Nearly 700% Driven by Sales from Sera Labs Product Lines
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced results for the quarter ended June 30, 2021, including the following highlights: Revenue of $2.1 million reflected an increase of nearly 700% from a year ago Gross profit rose 676% to...
Board of Directors
Chairman of the Board
Chief Executive Officer, Director
Chief Strategic Officer and Director, CEO of Wholly owned subsidiary, The Sera Labs.
(805) 410-9962 ext. 4
805 3rd Avenue #1430
New York, NY 10022
10100 Santa Monica Blvd., 8th Fl.
Los Angeles, CA 90067